Insider Trading & Ownership of Robert Lorne Hopfner

Location
San Francisco, CA
Summary
The estimated net worth of Robert Lorne Hopfner is at least $63,300,086 dollars as of 22 Dec 2025. Robert Lorne Hopfner is the Director, 10%+ Owner of Evommune, Inc. and owns shares of Evommune, Inc. (EVMN) stock worth about $63.22M. Robert Lorne Hopfner is the Director of Rallybio Corp and owns shares of Rallybio Corp (RLYB) stock worth about $80.7K.
Signature
/s/ Gregory S. Moss, Attorney-in-Fact
All Insider Reports
All Insider Reports

Follow Filing Activity

Follow Robert Lorne Hopfner and return when a new Insider Trading filing changes the record on this page.

This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean.

Sign up to save research and follow filings

Quick Takeaways

  • Robert Lorne Hopfner has 4 issuer positions tracked on this page.
  • Estimated disclosed ownership value: $63,300,086.
  • Recent insider filing activity is available below.

What Changed

  • Largest disclosed position: Evommune, Inc. ($63,219,381).
  • Past-year value change for that position: +$17,350.

Why This Matters

  • This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
  • You can cross-check role, issuer, and filing chronology directly against the SEC source.

Source Evidence

Filed on Form 4

Insider ownership context is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Ownership of Robert Lorne Hopfner

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
EVMN Evommune, Inc. Director, 10%+ Owner $63,219,381 +$17,350 +0.03% 19 Dec 2025
RLYB Rallybio Corp Director $80,705 13 May 2025
INZY Inozyme Pharma, Inc. Director $0 01 Jul 2025
PCVX Vaxcyte, Inc. Director 02 Jun 2021

Insider Transactions Reported by Robert Lorne Hopfner:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .